Purple Biotech
PPBT
15 hedge funds and large institutions have $2.4M invested in Purple Biotech in 2021 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 8 closing their positions.
3.01% less ownership
Funds ownership: 6.27% → 3.26% (-3%)
12% less funds holding
Funds holding: 17 → 15 (-2)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
27% less call options, than puts
Call options by funds: $593K | Put options by funds: $809K
44% less capital invested
Capital invested by funds: $4.25M → $2.4M (-$1.86M)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$420K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$302K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$87.7K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$68.1K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$26.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.53M |
| 2 |
O
OrbiMed
New York
|
-$1.47M |
| 3 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$110K |
| 4 |
Goldman Sachs
New York
|
-$100K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$96.1K |
PPBT Hedge Fund Activity: Q1 2021 in Review
15 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Purple Biotech (PPBT) for Q1 2021, worth a combined $2.4M — down 44% from $4.25M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of PPBT and 6 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 2 added.
The largest buyer was Renaissance Technologies, adding an estimated $420K. The largest seller was Morgan Stanley, cutting an estimated $1.53M.
- 15 institutional investors held Purple Biotech (PPBT) as of Q1 2021, down from 17 in Q4 2020.
- Funds reported $2.4M of Purple Biotech stock for Q1 2021, down 44% quarter-over-quarter.
- 6 funds opened new Purple Biotech positions in Q1 2021 and 8 closed out, a net change of -2 holders.
- The largest Purple Biotech buyer in Q1 2021 was Renaissance Technologies, an estimated $420K added.
- The largest Purple Biotech seller in Q1 2021 was Morgan Stanley, an estimated $1.53M sold.
Based on aggregated 13F filings for Q1 2021.